SEGMENT INFORMATION (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

Schedule of Segment Reporting Information

A reconciliation to the consolidated net loss for the three months ended March 31, 2026 and March 31, 2025 is included in the table below:

	Three Months Ended
(in thousands)	March 31, 2026		March 31, 2025
Revenue:
Screening revenue	$	39,832	$	29,133
Development services revenue	953		2,704
Total revenue	40,785		31,837
Costs and operating expenses:
Cost of screening revenue (exclusive of amortization of intangible assets) (1)	21,244		17,123
Cost of development services revenue (1)	376		1,171
Compensation	62,775		63,760
Depreciation and intangible assets amortization	37,222		37,679
Stock-based compensation	16,260		15,449
Professional Services	10,149		9,195
Cloud computing and information technology	6,480		6,743
Clinical Studies	5,944		5,922
Facilities	5,248		5,631
Laboratory supplies and research collaborations	1,420		3,667
Other segment expenses(2)	9,432		19,104
Total costs and operating expenses	176,550		185,444
Loss from Operations	(135,765)		(153,607)
Other income (expense):
Interest income	7,986		7,779
Other income (expense), net	256		(584)
Benefit from income taxes	34,336		40,199
Net Loss	$	(93,187)	$	(106,213)

(1) Cost of screening revenue (exclusive of amortization of intangible assets) and cost of development services revenue include stock-based compensation expense of $0.5 million and $0.8 million for the quarter ended March 31, 2026 and 2025.

(2) Other segment expenses primarily includes costs related to contractors and temporary labor, marketing expenses, and legal expenses, partially offset by refundable R&D tax expenses.